AIGH Capital Management’s Lipocine LPCN Stock Holding History

AIGH Capital Management’s Portfolio LPCN Stock Details LPCN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.6M	Buy	+200,000	New	+$1.74M	0.22%	36

Other funds holding LPCN

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Squadron Capital Management Westmont, Illinois $273M AUM

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Seven Fleet Capital Management Mountain View, California $318M AUM

Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIGH Capital Management's LPCN Position: Q1 2026 in Review

AIGH Capital Management opened a new position in Lipocine (LPCN) in Q1 2026: 200,000 shares worth $1.6M. The stake represents 0.22% of the portfolio and ranks #36 among its holdings.

47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

AIGH Capital Management held 200,000 shares of Lipocine worth $1.6M as of Q1 2026.
Lipocine was a new AIGH Capital Management position in Q1 2026.
Lipocine made up 0.22% of AIGH Capital Management's portfolio in Q1 2026, its #36 holding.
47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on AIGH Capital Management's 13F filing for Q1 2026, filed 30 Apr 2026.